Aerovate Therapeutics, Inc. (AVTE) Stock Analysis & Investment Frameworks
Aerovate Therapeutics, Inc. (AVTE) stock analysis on Invetso. Review Aerovate Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Aerovate Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Aerovate Therapeutics, Inc. Key Financial Metrics
- Market Cap: $77.68M
- Revenue: $N/A
- ROE: -60.53%
- ROIC: -41.91%
- Dividend Yield: 89.55%
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.